Immunovia AB (publ)
IMMVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -40.9% | 37.6% | 35.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$0 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 100% | -324.3% | -267.8% | 1,873.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | -$0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -11,752% | -18,822.9% | -16,694.3% | -19,742.7% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8,221.4% | -19,646.9% | -14,680.5% | -18,479.4% |
| EPS | -0.93 | -7.95 | -6.89 | -6.4 |
| % Growth | 88.3% | -15.4% | -7.7% | – |
| EPS Diluted | -0.93 | -7.95 | -6.89 | -6.4 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6,580.6% | -9,426.2% | -12,365% | -16,051.1% |